Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023

Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023

DelveInsight’s, “Angioimmunoblastic T cell Lymphoma – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Angioimmunoblastic T cell Lymphoma Understanding

Angioimmunoblastic T cell Lymphoma: Overview

Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). AITL is characterized by the transformation of a T-cell into a malignant cell. Abnormal, uncontrolled growth and multiplication (proliferation) of malignant T-cells may lead to enlargement of a specific lymph node region or regions; involvement of other lymphatic tissues, such as the spleen and bone marrow; and spread to other bodily tissues and organs. The initial symptoms are often vague and tend to come and go. Some affected individuals develop certain generalized (systemic) symptoms known as “B symptoms”. These symptoms are common in many different types of disorders. Such symptoms include persistent or repeated fever, unexplained weight loss (i.e., loss of at least 10 percent of normal body weight), and/or sweating, particularly at night (known as “night sweats”). The exact, underlying cause of AITL is unknown. It is believed that a dysfunctional immune system response to an unknown antigen ultimately leads to the development of the disorder. The Epstein-Barr virus, in particular, has been found in more than 90 percent of individuals with AITL. Diagnosis of Angioimmunoblastic T-cell lymphoma (AITL) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a biopsy of an affected lymph node or other affected areas such as the skin or bone marrow. Treatment of Angioimmunoblastic T-cell lymphoma is based on the assessment of the extent or “stage” of the disease progression, tumor size, presence or absence of certain symptoms, an individual's age and general health. It will help in characterizing the potential disease course and appropriate treatment approaches. A combination of chemotherapy and immunotherapy (chemoimmunotherapy) have been used.

""Angioimmunoblastic T cell Lymphoma - Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angioimmunoblastic T cell Lymphoma pipeline landscape is provided which includes the disease overview and Angioimmunoblastic T cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Angioimmunoblastic T cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angioimmunoblastic T cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Angioimmunoblastic T cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Angioimmunoblastic T cell Lymphoma.

Angioimmunoblastic T cell Lymphoma Emerging Drugs Chapters

This segment of the Angioimmunoblastic T cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angioimmunoblastic T cell Lymphoma Emerging Drugs

Azacitidine: Celgene

Azacitidine (5-azacytidine) is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine may induce antineoplastic activity by inhibition of DNA methyltransferase at low doses and cytotoxicity through incorporation into RNA and DNA at high doses. Covalent binding to DNA methyltransferase results in hypomethylation of DNA and prevents DNA synthesis. As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The drug is being evaluated in Phase III clinical trial to treat patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.

Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. A Phase II clinical trial evaluating Tislelizumab to treat Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma have been completed.

Further product details are provided in the report……..

Angioimmunoblastic T cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Angioimmunoblastic T cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Angioimmunoblastic T cell Lymphoma

There are approx. 10+ key companies which are developing the therapies for Angioimmunoblastic T cell Lymphoma. The companies which have their Angioimmunoblastic T cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Celgene.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Angioimmunoblastic T cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angioimmunoblastic T cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioimmunoblastic T cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioimmunoblastic T cell Lymphoma drugs.

Angioimmunoblastic T cell Lymphoma Report Insights

Angioimmunoblastic T cell Lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Angioimmunoblastic T cell Lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Angioimmunoblastic T cell Lymphoma drugs?

How many Angioimmunoblastic T cell Lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angioimmunoblastic T cell Lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angioimmunoblastic T cell Lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Angioimmunoblastic T cell Lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Celgene

BeiGene

Autolus Limited

SciTech Development, LLC

Wugen, Inc.

HUTCHMED

Kura Oncology

Key Products

Azacitidine

Tislelizumab

AUTO4

WU-CART-007

Fenretinide

HMPL-306